Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022Business Wire • 01/18/22
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/10/22
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/10/22
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 12/30/21
Follow The Leader: 3 Biopharma Stocks Displaying Relative StrengthZacks Investment Research • 12/29/21
Options Income Series: Earn High Income Safely And Consistently - December 2021Seeking Alpha • 12/25/21
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19Benzinga • 12/23/21
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19Business Wire • 12/22/21